Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

VDPHL01

Small molecule · developed by Veradermics

Phase 3 Most advanced trial
MANE Developer
2 Registered trials

What is VDPHL01?

VDPHL01 is an extended release oral tablet studied in androgenetic alopecia, also called male pattern baldness, and in hair loss in women.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Dermatology
Developer
Veradermics, Inc. (MANE)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07146022 Phase 3 Androgenetic Alopecia (AGA) Active not recruiting MANE
NCT06724614 Phase 2/3 Androgenetic Alopecia Active not recruiting MANE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

AGAAndrogenetic AlopeciaAndrogenetic Alopecia (AGA)Female Androgenetic AlopeciaHair LossMale Pattern Baldness

More from Veradermics

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the MANE page.

Follow MANE, the company behind VDPHL01

See MANE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MANE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.